Program Pipeline
iOmx is driving a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity and multimodal mechanisms of action, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise and in collaboration with Pharma partners, iOmx is committed to shaping the future of cancer therapy.
Apply Today
Clinical trial of OMX-0407 in angiosarcoma and renal cell carcinoma
The company’s lead candidate OMX-0407, a novel SIK inhibitor, is currently being investigated in a first-in-human clinical trial in patients with clear cell renal cell carcinoma and angiosarcoma. The trial is currently open for recruitment in angiosarcoma, details can be found here:
Program |
Target & Modality |
Indications |
Discovery |
Lead ID |
Lead Optimisation |
IND Enabling |
Clinical Ph I |
Clinical Ph II |
|---|---|---|---|---|---|---|---|---|
|
OMX-0407
|
SIKs & other oncology-relevant tyrosine kinases
Small molecule kinase inhibitor
|
Solid tumors |
|
|
|
|
|
|
|
OMX-0407 is an orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action of OMX 0407 combines immune sensitization and modulation of the tumor microenvironment with direct tumor cell cycle arrest, thereby driving tumor eradication. Clinical development of OMX-0407 
|
||||||||
|
IOMX-0675
|
LILRB1 / LILRB2 (ILT2 / ILT4)
Dual-targeting antibody
|
Solid tumors |
|
|
|
|
|
|
|
IOMX-0675 is a dual-targeting, best-in-class antibody, addressing a key immune-regulatory receptor family expressed on myeloid cells and other lymphoid immune cells, the LILR family. IOMX-0675 is a fully human, cross-specific, high-affinity ligand-blocking antibody that simultaneously neutralizes both, LILRB1 and LILRB2, while sparing LILRA1 and LILRA3, two closely related immune-activating receptor family members. The highly differentiated selectivity profile of IOMX-0675 unleashes the full anti-tumor potential by re-activating innate and adaptive immunity. 
|
||||||||
|
IOMX-0235
|
CCR9
Fc-enhanced antibody
|
Inflammatory bowel disease |
|
|
|
|
|
|
|
IOMX-0235 is a humanized, Fc-enhanced, and cynomolgus-monkey-cross-reactive monoclonal antibody for the treatment of inflammatory bowel disease (Ulcerative Colitis & Crohn’s Disease). IOMX-0235 is Fc-engineered to efficiently deplete CCR9-positive cells. IOMX-0235 has best-in-class potential in a clinically validated target class. 
|
||||||||
|
Discovery Programs
|
Undisclosed
Bispecifics & T cell engagers
|
Solid tumors |
|
|
|
|
|
|
|
iOmx is driving several discovery programs to add to its pipeline of next-generation immuno-oncology drugs, e.g., a tri-functional bispecific antibody synergistically blocking multiple immunosuppressive pathways as well as several T cell engager programs against novel undisclosed tumor-specific targets. 
|
||||||||
OMX-0407
6
Target & Modality |
SIKs & other oncology-relevant tyrosine kinases Small molecule kinase inhibitor |
Indications |
Solid tumors |
Phase |
Clinical Ph II |
OMX-0407 is an orally available, first-in-class spectrum-selective inhibitor of SIK (salt-inducible kinase) and other oncology-relevant tyrosine kinases. The mode of action of OMX 0407 combines immune sensitization and modulation of the tumor microenvironment with direct tumor cell cycle arrest, thereby driving tumor eradication.
Clinical development of OMX-0407
A first-in-human dose-escalation trial of OMX-0407 monotherapy in patients with previously treated unresectable solid tumors has started in March 2023 (NCT05826600), to be completed by mid 2024.
IOMX-0675
4
Target & Modality |
LILRB1 / LILRB2 (ILT2 / ILT4) Dual-targeting antibody |
Indications |
Solid tumors |
Phase |
IND Enabling |
IOMX-0675 is a dual-targeting, best-in-class antibody, addressing a key immune-regulatory receptor family expressed on myeloid cells and other lymphoid immune cells, the LILR family.
IOMX-0675 is a fully human, cross-specific, high-affinity ligand-blocking antibody that simultaneously neutralizes both, LILRB1 and LILRB2, while sparing LILRA1 and LILRA3, two closely related immune-activating receptor family members.
The highly differentiated selectivity profile of IOMX-0675 unleashes the full anti-tumor potential by re-activating innate and adaptive immunity.
IOMX-0235
3
Target & Modality |
CCR9 Fc-enhanced antibody |
Indications |
Inflammatory bowel disease |
Phase |
Lead Optimisation |
IOMX-0235 is a humanized, Fc-enhanced, and cynomolgus-monkey-cross-reactive monoclonal antibody for the treatment of inflammatory bowel disease (Ulcerative Colitis & Crohn’s Disease). IOMX-0235 is Fc-engineered to efficiently deplete CCR9-positive cells. IOMX-0235 has best-in-class potential in a clinically validated target class.
Discovery Programs
3
Target & Modality |
Undisclosed Bispecifics & T cell engagers |
Indications |
Solid tumors |
Phase |
Lead Optimisation |
iOmx is driving several discovery programs to add to its pipeline of next-generation immuno-oncology drugs, e.g., a tri-functional bispecific antibody synergistically blocking multiple immunosuppressive pathways as well as several T cell engager programs against novel undisclosed tumor-specific targets.